Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €19.54 EUR
Change Today +0.426 / 2.23%
Volume 0.0
CSUA On Other Exchanges
CSUA is not on other exchanges.
As of 1:37 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

corbion nv (CSUA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/15 - €20.70
52 Week Low
10/16/14 - €9.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CORBION NV (CSUA)

Related News

No related news articles were found.

corbion nv (CSUA) Related Businessweek News

View More BusinessWeek News

corbion nv (CSUA) Details

Corbion N.V. develops, manufactures, and markets biobased products worldwide. It operates through Biobased Ingredients and Biobased Innovations business units. The company primarily provides lactic acid, lactic acid derivatives, and lactides; and functional blends containing enzymes, emulsifiers, minerals, and vitamins. It offers high performance biobased products made from renewable resources, such as sugar, starch, or other carbohydrates in various markets, including bakery, meat, pharmaceuticals and medical devices, home and personal care, packaging, automotive, coatings, and adhesives. The company markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.

1,752 Employees
Last Reported Date: 08/12/15
Founded in 1919

corbion nv (CSUA) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €663.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €380.0K
Chief Technology Officer and Member of Manage...
Total Annual Compensation: €408.0K
Compensation as of Fiscal Year 2014.

corbion nv (CSUA) Key Developments

Corbion Announces Unaudited Consolidated Earnings Results for the Second Quarter and First Half of 2015; Provides Earnings Guidance for the Second Half of 2015 and Capex Guidance for the Full Year 2015

Corbion announced unaudited consolidated earnings results for the second quarter and first half of 2015. For the second quarter, the company reported EBITDA of EUR 40.1 million, growth of close to 50% for the quarter. This increase was driven by organic growth of 23.1% and a positive currency impact of 6.2 million. Net sales grew by 23.4% from EUR 188 million to EUR 232 million second quarter, influenced by stronger currencies, most notably the U.S. dollar. For the first half of 2015, the company reported EBITDA grew from EUR 52 million to EUR 77 million. CapEx was EUR 22 million. Net Sales were EUR 452.3 million compared to EUR 371.0 million a year ago. Capital expenditures in falf year 2015 amounted to EUR 27.3 million which includes the unexpected replacement investment as a result of the Grandview incident and the acquired lactic acid business from ADM. Cash flow from operating activities increased compared to year-end 2014 by EUR 8.3 million to EUR 35.3 million. Operating results was EUR 53.3 million compared to EUR 10.2 million a year ago. Result before tax was EUR 50.2 million compared to EUR 7.3 million a year ago. Results after taxes was EUR 34.6 million compared to EUR 1.2 million a year ago. Diluted earnings per share was EUR 0.54 compared to EUR 0.00 a year ago. Cash flow from operating activities was EUR 35.3 million compared to EUR 27.0 million a year ago. Net debt at half year-end 2015 was EUR 72.1 million. For the second half of 2015, the company expects a slightly lower EBITDA excluding one-off items, compared to first half of 2015. For the year, the company expects CapEx to a range of EUR 60 million to EUR 70 million.

Corbion and MedinCell Form Joint Venture to Supply Resorbable Polymers for Controlled Drug Release

Corbion and MedinCell are establishing a 50-50 joint venture for the supply of PEG (polyethyleneglycol) and PLA (polylactic acid) based co-polymers in the field of controlled release drug delivery.

Corbion N.V. to Report Q2, 2015 Results on Aug 12, 2015

Corbion N.V. announced that they will report Q2, 2015 results Pre-Market on Aug 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSUA:GR €19.54 EUR +0.426

CSUA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Balchem Corp $57.78 USD +1.06
Wessanen €9.36 EUR +0.24
Metabolix Inc $1.78 USD -0.1229
Sensient Technologies Corp $65.35 USD +1.50
Solazyme Inc $2.38 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation CSUA Industry Range
Price/Earnings 97.3x
Price/Sales 1.4x
Price/Book 2.6x
Price/Cash Flow 81.5x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORBION NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at